Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis

Journal of Sexual Medicine

Volumn 12, Issue 11, 2015, Pages 2095-2104

  Gao, Zhenli ^a   Yang, Diandong ^a   Yu, Luxin ^a   Cui, Yuanshan ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Flibanserin; Hypoactive Sexual Desire Disorder; Meta Analysis; Randomized Controlled Trial

Indexed keywords

FLIBANSERIN; PLACEBO; BENZIMIDAZOLE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 2 ANTAGONIST;

ARTICLE; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE SEXUAL DISTRESS SCALE REVISED SCORE; FEMALE SEXUAL FUNCTION INDEX; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; MAJOR CLINICAL STUDY; META ANALYSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SEXUAL BEHAVIOR; SYSTEMATIC REVIEW; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; LIBIDO; PSYCHOLOGY; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME;

BENZIMIDAZOLES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIBIDO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84954422480     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.13037     Document Type: Article

References (34)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Text Revision. Washington, DC: American Psychiatric Press; 2000:1-943.
2. Hatzichristou D, Rosen RC, DeRogatis LR, Low WY, Meuleman EJ, Sadovsky R, Symonds T. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010;7:337-348.
3. Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med 2009;6:1549-1560.
4. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med 2008;168:1441-1449.
5. Stahl SM. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr 2015;20:1-6.
6. Pfaus JG. Pathways of sexual desire. J Sex Med 2009;6:1506-1533.
7. Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet 2010;110:7-11.
8. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I, Rees M, Rodenberg CA, Rymer J, Schwenkhagen A, Sturdee DW. Testosterone treatment of HSDD in naturally menopausal women: The ADORE study. Climacteric 2010;13:121-131.
9. Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2012;9:1134-1148.
10. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-688.
11. Basson R, Brotto LA, Petkau AJ, Labrie F. Role of androgens in women's sexual dysfunction. Menopause 2010;17:962-971.
12. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. Pharmacology of flibanserin. CNS Drug Rev 2002;8:117-142.
13. Kennedy SH. Flibanserin: Initial evidence of efficacy on sexual dysfunction, in patients with Major Depressive Disorder. J Sex Med 2010;7:3449-3459.
14. Jadad AR. Randomised controlled trials. London: BMJ Publishing Group; 1998.
15. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. v.5.1. Sumter County, FL: The Cochrane Collaboration; 2011. Available at: http://www.cochrane-handbook.org/ updated March 2011.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
18. Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia MJ, Lesko L, Pyke R. Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY study. J Sex Med 2012;9:793-804.
19. Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia MJ, Wunderlich G, Pyke R. Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the VIOLET Study. J Sex Med 2012;9:1074-1085.
20. Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia MJ, Sand M. Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial. J Sex Med 2013;10:1807-1815.
21. Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia MJ, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: Results of the SNOWDROP trial. Menopause 2014;21:633-640.
22. Clayton AH, Goldfischer E, Goldstein I, DeRogatis L, Nappi R, Lewis-D'Agostino DJ, Kimura T, Hebert A, Pyke R. Validity of the decreased sexual desire screener for diagnosing hypoactive sexual desire disorder. J Sex Marital Ther 2013;39:132-143.
23. Stahl SM. The psychopharmacology of sex, Part 2: Effects of drugs and disease on the 3 phases of human sexual response. J Clin Psychiatry 2001;62:147-148.
24. US Food and Drug Administration. Draft guidance for industry. Female Sexual Dysfunction: Clinical development of drug products for treatment. 2000. Available at: http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm133202.htm.
25. Clayton AH, Dennerstein L, Fisher WA, Kingsberg SA, Perelman MA, Pyke RE. Standards for clinical trials in sexual dysfunction in women: Research designs and outcomes assessment. J Sex Med 2010;7:541-560.
26. Revicki DA, Margolis MK, Bush EN, DeRogatis LR, Hanes V. Content validity of the Female Sexual Function Index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2011;8:2237-2245.
27. Tignol J, Clayton AH, van Lunsen R, Nappi RE, Goldmeier D, Lewis-D'Agostino DJ, Pyke R, Wunderlich G. Using e-Diaries to measure sexual desire in women with HSDD. J Sex Med 2008;5:53.
28. DeRogatis L, Pyke R, McCormack J, Hunter A, Harding G. Does the Female Sexual Distress Scale-Revised cover the feelings of women with HSDD? J Sex Med 2011;8:2810-2815.
29. Goldfischer ER, Breaux J, Katz M, Kaufman J, Smith WB, Kimura T, Sand M, Pyke R. Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): Results from a randomized withdrawal trial. J Sex Med 2011;8:3160-3172.
30. Clayton AH, DeRogatis LR, Rosen RC, Pyke R. Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 1. For women with incomplete loss of desire or sexual receptivity. J Sex Med 2012;9:2027-2039.
31. Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM. Open label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med 2012;12:3180-3188.
32. Nappi RE. Why are there no FDA-approved treatments for female sexual dysfunction? Expert Opin Pharmacother 2015;16:1735-1738.
33. Roehr B. FDA committee recommends approval for "female Viagra. BMJ 2015;350:h3097.
34. Levine SB. Flibanserin. BMJ 2015;350:h3097.